UPLC-MS/MS法测定利奈唑胺原料和葡萄糖注射液中的叠氮类遗传毒性杂质
Determination of azide genotoxic impurity in linezolid API and glucose injection by UPLC-MS/MS
-
摘要: 建立了一种超高效液相色谱-串联质谱法（UPLC-MS/MS）测定利奈唑胺原料及其葡萄糖注射液中的遗传毒性杂质（R）-5-（叠氮甲基）-3-［3-氟-4-（4-吗啉基）苯基］-2-唑烷酮。采用Acquity UPLC HSS T3色谱柱（100 mm × 2.1 mm，1.8 μm）进行色谱分离，以0.1%甲酸水-0.1%甲酸乙腈（60∶40）为流动相，流速为0.3 mL/min进行等度洗脱；采用电喷雾离子化，在正离子模式下多反应监测模式进行监测。结果表明，该遗传毒性杂质在质量浓度4 ~ 12 ng/mL内线性关系良好，定量限为0.073 ng/mL，低、中、高浓度（80%、100%、120%限度浓度）加样溶液平均回收率分别为101.14%、100.59%和101.47%（RSD分别为0.73%、1.10%、0.91%）。同时，该遗传毒性杂质供试品溶液在6 d内稳定，3批制剂及2批原料中均未检出（R）-5-（叠氮甲基）-3-［3-氟-4-（4-吗啉基）苯基］-2-唑烷酮。
-
关键词:
- 超高效液相色谱-串联质谱法 /
- 利奈唑胺 /
- 遗传毒性杂质 /
- (R)-5-(叠氮甲基)-3-[3-氟-4-(4-吗啉基)苯基]-2-唑烷酮 /
- 含量测定
Abstract: A UPLC-MS/MS method was established for the determination of the genotoxic impurity (R)-5-(azidomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone in linezolid API and its glucose injection. Chromatographic separation was performed on a Waters Acquity UPLC HSS T3 column (100 mm × 2.1 mm, 1.8 μm) with 0.1% formic acid water-0.1% formic acid acetonitrile (60∶40) at a flow rate of 0.3 mL/min. The UPLC-MS/MS was equipped with electrospray ionization in positive ionization mode and multiple reaction monitoring mode. The results showed that the calibration curve was linear in the range of 4-12 ng/mL and the limit of quantification was 0.073 ng/mL.The average recoveries of the low, medium and high concentration (80%,100%,120% limit concentration) loading solutions were 101.14%, 100.59% and 101.47%, respectively (RSDs:0.73%, 1.10% and 0.91%, respectively).The sample solution was stable for 6 d.No genotoxic impurity of (R)-5-(Azidomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinonewas not detected in the samples of linezolid API and its glucose injection. -
-
[1] . Med Mal Infect，2005，35（9）：427-434. [2] Brickner SJ，Hutchinson DK，Barbachyn MR，et al. Synthesis and antibacterial activity of U-100592 and U-100766，two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections［J］. J Med Chem，1996，39（3）：673-679. [3] European Medicines Agency. ICH guideline M7（R1） on assessment and control of DNA reactive （mutagenic） impurities in pharmaceuticals to limit potential carcinogenic risk-step 5［EB/OL］.（ 2018-03-02 ）［2022-04-27 ］.https：//www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf .[4] Tuberculosis branch of Chinese Medical Association，Expert consensus writing group on linezolid anti-tuberculosis treatment. Expert consensus on anti-tuberculosis treatment with linezolid［J］. Chin J Tuberc Respir Dis（中华结核和呼吸杂志），2018，41（1）：14-19.
计量
- 文章访问数: 113
- HTML全文浏览量: 6
- PDF下载量: 334
下载:
